Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...
Last year, Bristol Myers Squibb put a spotlight on the kind of cash that comes with pharma’s conviction in a new oncology strategy. The drugmaker agreed to pay BioNTech $1.5 billion upfront and ...
Welcome to Biotech Spotlight, a series featuring companies creating breakthrough technologies and products. Today, we’re looking at ai3Bio, which recently came out of stealth to target autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results